奥西默替尼
医学
肿瘤科
肺癌
后天抵抗
内科学
液体活检
表皮生长因子受体
癌症
埃罗替尼
作者
Alessandro Leonetti,Veronica Cervati,Roberta Minari,Maura Scarlattei,Michela Verzè,Marianna Peroni,M. Pluchino,Francesco Bonatti,Fabiana Perrone,Giulia Mazzaschi,Agnese Cosenza,Letizia Gnetti,Paola Bordi,Livia Ruffini,Marcello Tiseo
标识
DOI:10.1016/j.cllc.2024.07.016
摘要
Despite the outstanding results achieved by osimertinib for the treatment of advanced EGFR-mutated NSCLC, the development of resistance is almost inevitable. While molecular mechanism responsible for osimertinib resistance are being mostly revealed, the definition of predictive biomarkers is crucial in order to identify patients at higher risk of progression and optimize treatment strategy.
科研通智能强力驱动
Strongly Powered by AbleSci AI